WallStreetZenWallStreetZen

NASDAQ: BVS
Bioventus Inc Stock

$4.55-0.15 (-3.19%)
Updated Apr 18, 2024
BVS Price
$4.55
Fair Value Price
$4.64
Market Cap
$360.20M
52 Week Low
$0.86
52 Week High
$6.08
P/E
-1.83x
P/B
2.08x
P/S
0.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$512.35M
Earnings
-$156.23M
Gross Margin
64.1%
Operating Margin
-22.54%
Profit Margin
-30.5%
Debt to Equity
3.4
Operating Cash Flow
$15M
Beta
1.31
Next Earnings
May 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BVS Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BVS ($4.55) is undervalued by 1.93% relative to our estimate of its Fair Value price of $4.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BVS ($4.55) is not significantly undervalued (1.93%) relative to our estimate of its Fair Value price of $4.64 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BVS due diligence checks available for Premium users.

Be the first to know about important BVS news, forecast changes, insider trades & much more!

BVS News

Valuation

BVS fair value

Fair Value of BVS stock based on Discounted Cash Flow (DCF)
Price
$4.55
Fair Value
$4.64
Undervalued by
1.93%
BVS ($4.55) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BVS ($4.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BVS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.83x
Industry
28.61x
Market
41.33x

BVS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.08x
Industry
3.63x
BVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BVS's financial health

Profit margin

Revenue
$135.4M
Net Income
-$6.1M
Profit Margin
-4.5%
BVS's Earnings (EBIT) of -$115.47M... subscribe to Premium to read more.
Interest Coverage Financials
BVS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$810.9M
Liabilities
$589.8M
Debt to equity
3.4
BVS's short-term assets ($268.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BVS's long-term liabilities ($414.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$10.4M
Investing
-$591.0k
Financing
-$14.0k
BVS's operating cash flow ($15.34M)... subscribe to Premium to read more.
Debt Coverage Financials

BVS vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
BVS$360.20M-3.19%-1.83x2.08x
SRDX$375.69M-0.49%67.67x3.08x
ANIK$377.63M-1.01%-4.51x1.78x
TCMD$333.71M-0.14%11.40x1.72x
PACB$391.21M+4.29%-1.21x0.56x

Bioventus Stock FAQ

What is Bioventus's quote symbol?

(NASDAQ: BVS) Bioventus trades on the NASDAQ under the ticker symbol BVS. Bioventus stock quotes can also be displayed as NASDAQ: BVS.

If you're new to stock investing, here's how to buy Bioventus stock.

What is the 52 week high and low for Bioventus (NASDAQ: BVS)?

(NASDAQ: BVS) Bioventus's 52-week high was $6.08, and its 52-week low was $0.86. It is currently -25.16% from its 52-week high and 429.07% from its 52-week low.

How much is Bioventus stock worth today?

(NASDAQ: BVS) Bioventus currently has 79,165,540 outstanding shares. With Bioventus stock trading at $4.55 per share, the total value of Bioventus stock (market capitalization) is $360.20M.

Bioventus stock was originally listed at a price of $19.21 in Feb 11, 2021. If you had invested in Bioventus stock at $19.21, your return over the last 3 years would have been -76.31%, for an annualized return of -38.13% (not including any dividends or dividend reinvestments).

How much is Bioventus's stock price per share?

(NASDAQ: BVS) Bioventus stock price per share is $4.55 today (as of Apr 18, 2024).

What is Bioventus's Market Cap?

(NASDAQ: BVS) Bioventus's market cap is $360.20M, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bioventus's market cap is calculated by multiplying BVS's current stock price of $4.55 by BVS's total outstanding shares of 79,165,540.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.